Angiotensin II (1-4), human

Modify Date: 2025-08-25 10:23:39

Angiotensin II (1-4), human structure	Common Name	Angiotensin II (1-4), human
	CAS Number	52580-29-7	Molecular Weight	551.59
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₃₇N₇O₈	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Angiotensin II (1-4), human

Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca2+ levels. Angiotensin II also acts at the Na+/H+ exchanger in the proximal tubules of the kidney[1][2].

Name	Angiotensin II (1-4), human

Description	Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca2+ levels. Angiotensin II also acts at the Na+/H+ exchanger in the proximal tubules of the kidney[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Angiotensin Receptor Research Areas >> Metabolic Disease
References	[1]. De Giusti VC, et al. Modulation of the cardiac sodium/bicarbonate cotransporter by the renin angiotensin aldosterone system: pathophysiological consequences. Front Physiol. 2014 Jan 17;4:411. [2]. Moon JY, et al. Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension. Electrolyte Blood Press. 2013 Dec;11(2):41-5.

Description

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Angiotensin Receptor

Research Areas >> Metabolic Disease

References

[1]. De Giusti VC, et al. Modulation of the cardiac sodium/bicarbonate cotransporter by the renin angiotensin aldosterone system: pathophysiological consequences. Front Physiol. 2014 Jan 17;4:411.

[2]. Moon JY, et al. Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension. Electrolyte Blood Press. 2013 Dec;11(2):41-5.